Healthcare IT Today September 9, 2021
Neuroglee Therapeutics (‘Neuroglee’), which builds personalized evidence-based digital therapeutics (DTx) and virtual care solutions to treat and manage patients with neurodegenerative diseases, announced today that it has closed a $10 million Series A funding round. The funding injection will enable Neuroglee to launch first-of-their-kind virtual neurology clinics for patients diagnosed with mild cognitive impairment related to difficult-to-treat conditions such as Alzheimer’s disease, while also advancing the company’s DTx pipeline.
Openspace Ventures and EDBI led the round. Additional capital has come from existing investors who have built transformational healthcare businesses, including Raman Singh, ex-CEO of Mundipharma, Biofourmis co-founders Kuldeep Singh Rajput and Wendou Niu, and a leading pharmaceutical company, Eisai Co., which is a strategic shareholder in the company.
“Neuroglee’s solution...